"Over the course of 2022 we made important pipeline progress and timely decisions through our pre-established go/no-go milestones related to the advancement of our development programs. Through this disciplined process, we have further prioritized our pipeline which enables us to focus our resources accordingly. Our active development programs continue to progress and we remain focused on driving enrollment in our ongoing DETECT trial and aim to continue exploring all strategic options for our Macrilen asset," commented Dr. Klaus Paulini, CEO of Aeterna.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on AEZS:
